Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via “patch” technology and utilizes Micron’s first-in-class dissolvable microarray technologyResearch builds on Emory’s research on influenza vaccines self-administered via Micron’s microarray technology ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Emory University and Micron Biomedical today announced the first clinical trial of a novel rotavirus vaccine, CC24, delivered via dissolvable microarray technology is now enrolling parti ...